Free Trial

Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 66.8% in September

Sunshine Biopharma logo with Medical background

Sunshine Biopharma, Inc. (NASDAQ:SBFM - Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 370,900 shares, a growth of 66.8% from the September 15th total of 222,300 shares. Approximately 30.4% of the company's shares are sold short. Based on an average daily trading volume, of 162,900 shares, the short-interest ratio is presently 2.3 days.

Sunshine Biopharma Price Performance

SBFM stock traded down $0.09 on Friday, hitting $2.97. 70,780 shares of the company were exchanged, compared to its average volume of 127,536. Sunshine Biopharma has a twelve month low of $2.42 and a twelve month high of $679.80. The business's fifty day moving average is $2.80 and its two-hundred day moving average is $2.22. The stock has a market capitalization of $69.53 million, a price-to-earnings ratio of -0.23 and a beta of 1.39.

Sunshine Biopharma (NASDAQ:SBFM - Get Free Report) last released its quarterly earnings results on Friday, August 16th. The company reported ($9.94) earnings per share for the quarter. The firm had revenue of $9.30 million for the quarter. Sunshine Biopharma had a negative net margin of 12.07% and a negative return on equity of 16.09%.

Sunshine Biopharma Company Profile

(Get Free Report)

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.

See Also

→ Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad)

Should you invest $1,000 in Sunshine Biopharma right now?

Before you consider Sunshine Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sunshine Biopharma wasn't on the list.

While Sunshine Biopharma currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines